S15: Rapidly delivering the next generation of vaccines and proteins using Pfenex’s expression technology

The ability to quickly and cost effectively develop and manufacture the next generation of therapeutic proteins and vaccines is key to delivering the pipelines of today and tomorrow. Small scale high-throughput technologies and  the Pseudomonas fluorescens based expression system allows one to quickly select and develop the desired strain and process from discovery to commercialization.

Case studies of rapid simultaneous production strain selection and development of high productivity fermentation processes using small scale bioreactors and their subsequent successful scale-up will be presented. Quality data will also be presented for Pfenex’s CRM197, a carrier protein, showing that the Pfenex’s version produced in Pseudomonas fluorescens is identical in both structure and function to the protein produced in Corynebacterium diphtheria. Pfenex’s approach to developing the next generation of proteins as well as its current portfolio of reagents allows one to speed their products/proteins to the clinic faster.